u/LionLukeWay · 266d agono track record yet
DD: SLS to $100+: The "New Math" Moonshot
SELLAS Life Sciences is approaching a critical window for its Phase 3 REGAL trial with delayed event rates suggesting the GPS drug arm significantly extends survival. The FDA's new January 2026 Bayesian guidance allows early superiority stopping without hitting 80 deaths, and a February superiority call could trigger M&A interest from Merck seeking bolt-on oncology assets, with acquisition valuations potentially reaching $100+ per share.
At post $4.40Now $10.72+143.6% since postedas of Oct 19, 11:31 AM ET
1d-9.8%
3d-14.3%
1w-5.5%
1m+11.8%
3m+10.9%
6m+157.3%
1y—